

Salvensis

contact: information@salvensis.org

- Not for profit virtual drug discovery organisation



Dr Mark Gardner
Computational &
Medicinal Chemist





Dr Tanya Parkinson
Infectious Diseases
Biologist



Dr Andy Bell
Medicinal Chemist



Mike Palmer
Medicinal Chemist




Schistosomiasis project

- PZQ – great drug but...
- Our goal – new clinical candidate improving on PZQs deficiencies

High throughput screening identifies novel lead compounds with activity against larval, juvenile and adult *Schistosoma mansoni*


Nuha R. Mansour^{†*}, Ross Paveley^{†*}, J. Mark F. Gardner[‡], Andrew S. Bell[‡], Tanya Parkinson[‡] and Quentin Bickle[†]

[†]Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom and [‡]Salvensis, Discovery Park House, Discovery Park, Ramsgate Road, Sandwich, Kent CT13 9ND, United Kingdom.



Malaria project

- Goal: Identify Pf PDE inhibitors with anti-malarial activity
- Prof. David Baker, Dr Laura Drought, LSHTM
- CiC project approach: screening hPDE compounds from GSK & Pfizer (some with known blood stage malaria activity)
- MMV keen to support project



hPDE9 (3JSI) with some differences between h & Pf identified
(data from Manallack et al, JCAMD 2011, 753)